59568
document
Pregnancy outcome and glycemic control in women with type 1 diabetes : a retrospective comparison between CSII and MDI treatment . AIM Present study was aimed to evaluate glycemic control and maternal-fetal outcome in pregnant type 1 diabetic patient treated with continuous subcutaneous insulin infusion ( CSII ) or multiple daily injections of insulin ( MDI ) . PATIENTS AND METHODS A retrospective observational study included thirty-four pregnant type 1 diabetic patients . Patients were divided into two group , CSII treated group ( n=14 ) and MDI treated group ( n=20 ) . The HbA1c level and maternal-fetal outcome were evaluated in both the treatment group . Outcome parameters such as glycemic control ( HbA1c ) , hypoglycemic events , time and mode of delivery and labor results ( abortion , premature labor , perinatal mortality , neonatal weight , Apgar score , neonatal hypoglycaemia , presence of congenital abnormalities ) were analyzed . RESULTS Pregnancy outcome and glycemic control in pregnant type 1 diabetic patients treated with CSII and MDI were evaluated and compared . Two groups were compared for their epidemiological parameters , although patients on CSII treatment had longer duration of diabetes compared to MDI treated group . Reduction in HbA1c level was higher in CSII treated patients at first ( CSII : 0.9 % vs MDI : 0.46 % ) , second ( CSII : 1.58 % vs MDI : 0.78 % ) and third trimester ( CSII : 1.74 % vs MDI : 1.09 % ) of pregnancy compared to MDI treated patients . Duration of pregnancy and new born baby weight were founded similar in both group . Moreover , the rate of abortion , preterm labor , cesarean section and hypoglycemia in new born were founded less in CSII treated group compared to MDI treated group and Apgar score was significantly ( p < 0.05 ) higher in CSII treated group compared to MDI treated group . CONCLUSION Results of present study revealed that the CSII gives better glycemic control and pregnancy outcome in pregnant type 1 diabetic patients compared to MDI treatment . CSII also decreases the daily insulin requirement compared MDI .
59569
Intervention_Pharmacological
CSII
59570
Intervention_Pharmacological
MDI
59571
Intervention_Pharmacological
continuous subcutaneous insulin infusion ( CSII )
59572
Intervention_Pharmacological
multiple daily injections of insulin ( MDI )
59573
Intervention_Pharmacological
CSII
59574
Intervention_Pharmacological
MDI
59575
Outcome_Physical
glycemic control
59576
Outcome_Physical
glycemic control and maternal-fetal outcome
59577
Outcome_Physical
glycemic control ( HbA1c
59578
Outcome_Physical
hypoglycemic events
59579
Outcome_Physical
time and mode of delivery and labor results ( abortion , premature labor , perinatal mortality , neonatal weight , Apgar score , neonatal hypoglycaemia , presence of congenital abnormalities
59580
Outcome_Physical
Pregnancy outcome and glycemic control
59581
Outcome_Physical
longer duration of diabetes
59582
Outcome_Physical
Reduction in HbA1c level
59583
Outcome_Physical
Duration of pregnancy and new born baby weight
59584
Outcome_Physical
rate of abortion , preterm labor , cesarean section and hypoglycemia in new born
59585
Outcome_Physical
Apgar score
59586
Participant_Sex
women
59587
Participant_Condition
type 1 diabetes
59588
Participant_Condition
in pregnant type 1 diabetic patient
59589
Participant_Sample-size
thirty-four
59590
Participant_Condition
pregnant type 1 diabetic patients
59591
Participant_Sample-size
n=14
59592
Participant_Sample-size
n=20
59593
Participant_Condition
pregnant type 1 diabetic